PubMed Health⌕ Search

Biomedical subjects

R Brito

Publications and source records attributed to R Brito.

24 records · Page 2Linked to original sources

[Exercise test: abnormal ST segments restricted to recovery phase].

PURPOSE: To determine the incidence of atherosclerotic coronary artery disease (CAD) and or myocardial ischemia in patients (pt) with abnormal ST segments restrict to recovery phase (RRAST) of exercise testing (ET). MATERIAL AND METHOD: Retrospective study in 19 non consecutive pt with RRAST, related to coronary arteriography or exercise planar scyntillography (18 men, 58 +/- 9 years, 18 asymptomatic). RESULTS: RRAST corresponded to ST segment depression from 1 to 4 mm, with T inversion during early recovery (2 pt); late (14 pt) or both (4 pt). It was documented CAD (14 pt and 9) with artery-by-pass surgery); hypertensive myocardiopathy with normal coronary (3 pt), and mitral prolapse valve (1 pt). In 13 pt with coronary arteriography or exercise scyntillography, within the first 6 months from exercise testing, myocardial ischemia was confirmed in 8 pt in 3 pt, successive exercise testing showed RRAST reproductive in 2 cases. CONCLUSION: The authors report the high incidence of CAD and or transitory hypoperfusion during myocardial scyntillography in symptomatic men with middle age with RRAST during exercise testing.

Adult↗

[Obtaining antibodies and development of an immunoassay for the detection of Escherichia coli proteins in preparations of human recombinant gamma interferon].

The present paper refers to the obtainment of polyspecific antisera directed against Escherichia coli host strain used to produce recombinant human gamma interferon (rec. hum. gamma IFN). The antisera were obtained by the cascade immunization method. The animals (n = 3) were initially immunized with an E. coli protein preparation (EcPp) of the host strain obtained from a blank run which assures the absence of the rec. hum. gamma IFN protein. Afterwards, consecutive immunizations were carried out with the less immunogenic proteins. To obtain those proteins, EcPp is passed through a column containing antibodies purified from previous inoculations coupled to a gel matrix. In this way, the proteins that have not been recognized by the immune system in that moment (e.g. do not have their corresponding antibodies coupled to the column) are separated an used to reimmunize the animals. The analyses of the antisera by Western blotting show a progressive recognition of the host strain proteins by the antisera with the progression of the cascade method. The recognition is evident through all the molecular weight range. Those antisera were used as quality control of the recombinant protein, by quantification of the host strain protein contaminants using a multiantigenic ELISA. The detection limit of that system was 3.125 ng/mL and the quantification limit 6.25 ng/mL.

Animals↗